Can Aehr's $22M AI Order Unlock a Bigger WLBI Opportunity?

Aehr Test Systems, Inc. AEHR has secured a $22 million follow-on production order from its lead AI processor customer, signaling growing adoption of wafer-level burn-in (WLBI) as AI chips become more complex and costly. The systems are expected to ship over the next six months to the customer’s high-volume manufacturing partner in Taiwan, supporting production of advanced AI training and inference processors.

The order includes multiple FOX-XP systems, FOX WaferPak contactors and Auto Aligners. Each FOX-XP can simultaneously test and burn in nine 300mm wafers, enabling manufacturers to identify early-life reliability issues before chips are packaged. This can help reduce the risk of committing expensive HBM, substrates and interposers to dies that may later fail reliability screening, making WLBI increasingly relevant as AI package complexity rises.

The latest win builds on AEHR’s momentum. In February, the company received a $14 million order from the same lead AI processor customer. It reported a $100.6 million effective backlog at the end of fiscal 2026, while fiscal 2027 revenue guidance of $130-$150 million points to substantial year-over-year growth. Record quarterly bookings of $60.7 million at the fiscal fourth-quarter end also indicate strong demand for its test and burn-in solutions across multiple applications.

Additionally, the company is engaging with additional semiconductor companies and hyperscalers following positive WLBI benchmark results, while targeting applications spanning AI accelerators, CPUs, network processors, memory and HBM. As chip values, power requirements and advanced packaging complexity increase, broader adoption of WLBI could create a meaningful growth avenue for Aehr.

AEHR Faces Stiff Competition

Aehr operates in a highly competitive semiconductor test equipment market, contending with strong rivals such as Teradyne, Inc. TER and FormFactor, Inc. FORM.

Teradyne is benefiting from robust AI-related semiconductor testing demand, with its semiconductor test business gaining from higher testing requirements for advanced chips. Strong orders from AI and high-performance computing applications position TER well as chip complexity and testing intensity continue to rise.

FormFactor is benefiting from rising AI and HBM test requirements, with demand for advanced probe cards supported by increasingly complex processors and packaging. FORM’s wafer-level testing capabilities position the company well as semiconductor manufacturers increase testing intensity to improve yield and reliability.

AEHR’s Share Price Performance, Valuation & Estimates

AEHR’s shares have surged 79.5% over the past month, outperforming the broader industry’s 7.9% growth.

Image Source: Zacks Investment Research

Aehr shares are trading at a premium. In terms of the forward 12-month price-to-sales (P/S), AEHR is trading at 27.11X, higher than the industry’s 6.31X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for AEHR’s fiscal 2027 earnings is projected at 70 cents per share, a sharp increase from 3 cents a year ago.

Image Source: Zacks Investment Research

Aehr currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research